The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?

Takashi Matsumoto; Masaki Shiota

doi:10.21037/tau-20-866

The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	2289-2291
Number of pages	3
Journal	Translational Andrology and Urology
Volume	9
Issue number	5
DOIs	https://doi.org/10.21037/tau-20-866
Publication status	Published - Oct 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Reproductive Medicine
Urology

Access to Document

10.21037/tau-20-866

Cite this

@article{cb9f0cad15da4eaba679b2c7760d7528,

title = "The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?",

author = "Takashi Matsumoto and Masaki Shiota",

year = "2020",

month = oct,

doi = "10.21037/tau-20-866",

language = "English",

volume = "9",

pages = "2289--2291",

journal = "Translational Andrology and Urology",

issn = "2223-4683",

publisher = "AME Publishing Company",

number = "5",

}

TY - JOUR

T1 - The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers

T2 - Where is the clinically relevant hotspot for prostate cancer?

AU - Matsumoto, Takashi

AU - Shiota, Masaki

PY - 2020/10

Y1 - 2020/10

UR - https://www.scopus.com/pages/publications/85096196045

UR - https://www.scopus.com/pages/publications/85096196045#tab=citedBy

U2 - 10.21037/tau-20-866

DO - 10.21037/tau-20-866

M3 - Comment/debate

AN - SCOPUS:85096196045

SN - 2223-4683

VL - 9

SP - 2289

EP - 2291

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

IS - 5

ER -

The established risk of prostate cancer comorbidity in BRCA1/2 mutation carriers: Where is the clinically relevant hotspot for prostate cancer?

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this